| Ytd | -65.99% | |
| 1y | -77.03% |
| Open | 0.37 | Prev Close | 0.36 | Low | 0.33 | High | 0.38 | Mkt Cap | 11.02M |
| Vol | 130.49K | Avg Vol | 258.98K | EPS | -1.77 | P/E | -0.20 | Forward P/E | -5.33 |
| Beta | 2.75 | Short Ratio | 3.27 | Inst. Own | 23.33% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 0.83 | 200-d Avg | 1.15 | 1yr Est | 12.00 |
Senti Biosciences (NASDAQ: SNTI - Get Free Report) will likely be issuing its Q2 2026 results before
Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.6% to $0.18 during Thursday's
Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday
Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) ("SBH" or the "Company") today annou